
/ EXPERTISE
Where strategy meets execution
Stratt operates at the commercial frontier of pharma launch — from first evidence signal through to loss of exclusivity. Additional domains launching 2026.
Clinical success doesn't guarantee commercial success.
58% of pharma launches miss pre-launch expectations. The gap is structural, not scientific. Explore where Stratt closes it.
/01
Phase I - III
Where commercial logic should start - not end.
Target selection, indication sequencing, and asset prioritisation carry embedded commercial assumptions that compound in value or cost across the entire lifecycle.
Discover how we accelerate trial operations
/02
Phase I - III
Where commercial logic should start - not end.
Target selection, indication sequencing, and asset prioritisation carry embedded commercial assumptions that compound in value or cost across the entire lifecycle.
/03
Phase I - III
Where commercial logic should start - not end.
Target selection, indication sequencing, and asset prioritisation carry embedded commercial assumptions that compound in value or cost across the entire lifecycle.